Skip to main content
Premium Trial:

Request an Annual Quote

Novartis' Genoptix Licenses Trovagene Marker for AML Services

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted to Genoptix a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia.

Genoptix, a Novartis company, will pay Trovagene upfront and royalty payments. Further terms of the deal were not disclosed.

Trovagene holds the exclusive worldwide license to the patent around NPM1 and has granted sublicenses to offer mutation analysis of the protein as a laboratory service for the diagnosis and monitoring of patients with AML to Quest Diagnostics, Laboratory Corporation of America, Münchner Leukamielabor in Germany, Skyline Labs in the Netherlands, and others.

NPM1 mutation testing is recommended by the national Comprehensive Cancer Network, which sets clinical treatment standards for a number of cancers, Trovagene said.

The San Diego-based molecular diagnostics firm also has deals to manufacture and sell NPM1 mutation kits to Asuragen and Ipsogen, which was acquired by Qiagen last year.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.